小鼠结核分枝杆菌耐药模型的建立与评价

目的 建立小鼠结核分枝杆菌耐利福平株静脉感染小鼠模型.方法 30只BALB/c雌性小鼠经尾静脉感染结核分枝杆菌耐利福平株每只106 CFU,观察小鼠一般状况,并分别在感染后6周、10周、14周处死小鼠,进行脾、肺组织病理切片、抗酸染色、计脏器荷菌数.结果 感染后小鼠体重呈逐渐上升趋势,脏器病理变化随时间推移由急性炎症逐...     

气雾攻击法感染结核病小鼠模型的建立及其综合评价

目的 模拟自然感染方式建立结核病小鼠模型,并对其病理变化进行综合评价.方法 通过气雾攻击方式将结核分枝杆菌H37Rv接种至C57BL/6J小鼠体内.在感染后的4周、6周、8周对小鼠进行micro-CT活体动态扫描,无菌分离肺脏和脾脏,肉眼观察病变情况,活菌菌落计数,组织病理检测(HE和抗酸染色).结果 肉眼观察和micro-CT扫描发现,不同时间小鼠肺部感染情况逐渐加重,至感染后第8周时病变弥漫至整个肺部;HE染色肺组织出现弥漫性肉芽肿样实变;抗酸染色可见结核分枝杆菌.结论 通过大体病变、病理、影像、菌落计数几个方面对建立的小鼠模型进行综合分析,证明利用气雾攻击法感染的结核病小鼠模型建立成功;该模型在形成病变时与结核患者的情况存在一定差异,对其完善的综合评价有助于在相关研究中对该小鼠模型的合理应用.     

表达HBHA和hIL-12融合蛋白的重组耻垢分枝杆菌在小鼠体内诱导的免疫应答及保护力

目的:测定表达肝素结合血凝素(HBHA)和人白细胞介素12(hIL-12)融合蛋白的重组耻垢分枝杆菌在小鼠体内诱导产生的免疫应答及对结核分枝杆菌感染的保护作用。方法:将表达HBHA和hIL-12融合蛋白的重组耻垢分枝杆菌采用同源加强免疫的方法免疫小鼠,检测小鼠外周血中IFN-γ、IL-2和IL-12的表达水平;用结核分枝杆菌感染免疫小鼠,检测小鼠肺部荷菌量和组织病理变化。结果:表达HBHA和hIL-12融合蛋白的重组耻垢分枝杆菌诱导小鼠产生以IFN-γ、IL-2分泌量增加为主的Th1型免疫应答,并能有效减少感染小鼠肺部结核分枝杆菌的荷菌量和病理损伤。结论:表达HBHA和hIL-12融合蛋白的重组耻垢分枝杆菌免疫小鼠可诱导产生与卡介苗相当的保护作用,可能成为控制结核病的有效疫苗。     

结核分枝杆菌持续感染小鼠模型的建立及其免疫特征

为建立小鼠结核分枝杆菌持续感染模型并研究其免疫应答特征,选取雌性C57BL/6小鼠,经尾静脉感染结核分枝杆菌H37Rv株,并以异烟肼和利福平联合治疗。分别于感染后4、8、12周处死小鼠,用平板法计数肺和脾荷菌数,酶联免疫吸附试验(ELISA)检测血清中特异性抗体水平及亚类,流式细胞术检测CD4+脾淋巴细胞经结核分枝杆菌抗原——纯化蛋白衍生物(PPD)刺激后分泌细胞因子的细胞比例。结果显示,感染4周后小鼠肺和脾荷菌数lg CFU分别达3.67±0.25和3.54±0.24,至少持续8周;药物治疗可有效降低脏器荷菌数。感染12周后,感染组血清中抗结核分枝杆菌特异性抗体水平显著升高(P0.01),且以IgG1为主;治疗组总IgG抗体水平显著低于感染组(P0.01),且IgG2a相对较高(P0.05)。感染组CD4+脾淋巴细胞中γ干扰素(IFN-γ)和白细胞介素2(IL-2)分泌细胞比例显著增加(P0.01和P0.001),而IL-4分泌细胞比例显著降低(P0.01);治疗组IL-2和IL-4分泌细胞比例显著低于正常组(P0.05和P0.01)。本研究建立的小鼠结核分枝杆菌持续感染模型有望用于结核病治疗性疫苗和药物的研发及筛选。     

Ⅱ型糖尿病并发结核病小鼠模型的建立及评价

目的建立Ⅱ型糖尿病并发结核病小鼠模型,对其肺组织病变过程进行评价。方法高脂高糖饲料喂养C57BL/6J小鼠,腹腔注射STZ,建立Ⅱ型糖尿病小鼠模型。采用滴鼻的方式将结核分枝杆菌H37Rv接种至糖尿病小鼠体内,建立糖尿病并发结核病小鼠模型。分别于感染后的1~8周、10周及12周解剖小鼠,肉眼观察小鼠肺脏病变情况,活菌菌落计数,肺组织行HE及抗酸染色,镜下观察病理学改变。结果肉眼观察发现,随着感染时间的增长肺部感染情况逐渐加重,至第8周时病灶达到全肺的80%,第10周时病变范围开始缩小;感染8周后HE染色肺组织出现典型的肉芽肿结构,至第10周部分病变肺组织出现修复现象;抗酸染色可见结核分枝杆菌。结论从大体病变、菌落计数及病理改变等方面对小鼠模型进行评价,发现糖尿病并发结核病小鼠模型较单一的结核病小鼠模型具有病变出现早,病程进展快等特点,与临床患者的某些阶段表现类似,因此实验构建的糖尿病并发结核病小鼠模型基本成功。     

Rpf结构域及其突变体对MTB感染小鼠的免疫治疗作用

目的:观察复苏促生长因子Rpf结构域(Rpfd)及其突变体E54K (Rpfd1),E54A (Rpfd2)和E54K+ D48A (Rpfd3)对MTB感染小鼠的免疫治疗作用.方法:表达、纯化Rpfd及其突变体Rpfd1,Rpfd2和Rpfd3.结核毒株H37RV从尾静脉感染BALB/c小鼠,剂量为1× 105C F U.感染4w后,随机分为6组,在感染后4w、6w和8周分别腹部皮下注射含50 μg/ml相应蛋白Rpfd、Rpfd1、Rpfd2、Rpfd3的生理盐水,同时设异烟肼(INH,54.25 mg/L)联合利福平(RFP,52.5 mg/L)治疗组.在感染后11w和13w,分别取一侧肺脏计数荷菌数.将各时间点的感染小鼠另一侧肺脏固定后进行组织学观察.结果:表达产物均可与抗-Rpf结构域单抗特异性结合,相对分子量约为32 kDa.感染后11w和13w,Rpfd、Rp fd1、Rpfd2治疗组肺部荷菌量明显少于Rpfd3治疗组和生理盐水组(P＜0.05),但其对肺部MTB的控制未达到INH+RFP联合治疗的效果(P＜0.05).结论:MTB感染小鼠后,利用Rpfd蛋白进行免疫治疗,发现Rpfd及其突变体Rpfd1和Rpfd2蛋白能够显著的降低肺脏荷菌数,并且诱导淋巴细胞的增值.为利用Rpf结构域突变体制备MTB的免疫治疗疫苗提供了理论依据和实验基础.     

利用无传染性耻垢分枝杆菌建立小鼠结核病模型的探索

目的:利用耻垢分枝杆菌(M.smegmatismc2155)建立C57BL/6小鼠结核病模型。方法:每天以高剂量(5×107CFU)耻垢分枝杆菌给C57BL/6小鼠腹腔注射,连续感染4周,检测耻垢分枝杆菌对小鼠的致病性。分别于2周和4周处死小鼠,无菌条件下解剖小鼠取肺、脾脏组织匀浆,进行组织内细菌活力检测;通过嗜酸性染色进行分枝杆菌的鉴定;同时进行病理切片的制备,观察肺和脾脏组织的病理变化;最后进行菌体DNA的提取和基因检测,根据上述指标确定小鼠结核病模型的建立是否成功。结果:腹腔感染小鼠2周后,模型组小鼠只有脾脏组织匀浆液出现抗酸染色阳性菌落,肺部组织未见阳性菌落。腹腔感染小鼠4周后,模型组小鼠肺、脾脏组织匀浆液中均可见大量抗酸染色阳性的菌落;组织病理学观察结果显示:小鼠肺组织主要表现为以中性粒细胞为主的炎性病变;基因检测结果表明:模型组小鼠肺组织匀浆液中可检测到耻垢分枝杆菌特异性3-磷酸甘油醛脱氢酶(gap)基因,而脾脏组织未扩增出耻垢分枝杆菌特异性基因。结论:通过腹腔注射无致病性耻垢分枝杆菌方法,成功建立C57BL/6小鼠结核病发生模型,为结核分枝杆菌与宿主相互作用研究提供安全的疾病模型。     

轮状病毒致BALB/c小鼠肠道外感染后淋巴细胞亚群变化的研究

目的建立小鼠肠道外感染轮状病毒(Rotavirus,RV)动物模型,观察该模型动物发病时的细胞免疫功能状态。方法通过腹腔注射RV,建立小鼠肠道外感染RV的模型。分别在病毒接种后第3天及第7天通过摘除眼球取血,流式细胞仪检测T细胞亚群。同时处死动物,无菌取出肺脏、肝脏和脾脏进行组织病理学检查。设立正常对照组。结果小鼠肠道外感染RV成功(可见到肺脏、肝脏和脾脏非特异性病毒感染性炎性病变)。淋巴细胞亚群测定:实验组CD3、CD4及CD4/CD8比值均较对照组明显降低(P0.01)。结论RV引起小鼠肠道外脏器肺脏、肝脏和脾脏组织病变的同时,机体免疫功能亦明显降低。     

滴鼻途径建立鼠结核病模型的探讨

目的 探讨滴鼻途径建立BALB/C小鼠结核分枝杆菌感染的模型的可行性.方法 人型Mtb H_(37)Rv标准株经腹腔接种小鼠,取小鼠腹腔冲洗液100 μl接种改良罗-琴氏培养基.刮取上述培养基上生长4周已恢复毒力的结核分枝杆菌H_(37)Rv标准株,加0.05%Tween80生理盐水磨菌制成悬液,菌落计数,计数后稀释悬液为5×10~3 CFU/50 μl、5×10~4 CFU/50 μl、5×10~5 CFU/50 μl及50 μl生理盐水分别感染4组Balb/c小鼠,制作结核分枝杆菌感染模型.结果 滴鼻感染小鼠4周后,所有小鼠肺、脾组织中均可见抗酸阳性菌,在感染小鼠肺、脾组织匀浆均培养出Mtb.肺组织病理改变明显,正常肺泡结构消失,以充血实变、淋巴细胞、巨噬细胞浸润为主,增生性改变不明显,未见明显的组织坏死.脾组织病理改变主要是巨噬细胞和淋巴细胞增生.结论 滴鼻感染途径建立小鼠结核病模型简便、可行,为进一步研究开发重组BCG疫苗对鼠结核病的防治打下良好的基础. 0~4 CFU/50 μl、5×10~5 CFU/50 μl及50 μl生理盐水分别感染4组Balb/c小鼠,制作结核分枝杆菌感染模型.结果 滴鼻感染小鼠 周后,所有小鼠肺、脾组织中均可见抗酸阳性菌,在感染小鼠肺、脾组织匀浆均培养出Mtb.肺组织病理改变明显,正常肺泡结构消失,以充血实变、淋巴细胞、巨噬细胞浸润为主,增生性改变不明显,未见明显的组织坏死.脾组织病理改变主要是巨噬细胞和淋巴细胞增生.结论 滴鼻感染途径建立小鼠结核病模型简便、可行,为进一步研究开发重组BCG疫苗对鼠结核病的防治打下良好的基础. 0~4 CFU/50 μl、5×10~5 CFU/50 μl及50 μl生理盐水分别感染4组Balb/c     

应用多重PCR方法检测石蜡包埋组织标本中的分枝杆菌DNA

应用多重PCR方法检测并鉴别石蜡包埋组织中的结核分枝杆菌复合体与非结核分枝杆菌DNA扩增片段类型 ,为结核分枝杆菌复合体感染与非结核分枝杆菌感染的病理学诊断提供一种补充的鉴别诊断方法。应用三对具有特异性的寡核苷酸引物 ,进行多重PCR扩增。这三对引物分别对应于分枝杆菌 6 5kD表面抗原、结核分枝杆菌插入序列IS6 1 1 0及人类β 珠蛋白基因的部分序列 ,其扩增产物分别为 3 83bp、1 2 3bp和 2 6 8bp。此种多重PCR方法检测的灵敏度为 0 6pg。经多重PCR扩增后进行凝胶电泳 ,结核分枝杆菌复合体 (结核分枝杆菌、牛型结核分枝杆菌、BCG)均可见 3 83bp、1 2 3bp片段 ,而非结核分枝杆菌 (鸟、龟、瘰疬、蟾蜍、堪萨斯、胞内、耻垢分枝杆菌 )仅见 3 83bp片段 (猿猴分枝杆菌与结核分枝杆菌复合体相同 )。与上述相比 ,分枝杆菌感染的临床标本分别增加了一条 2 6 8bp片段。对 2 0 9例临床初步诊断为淋巴结结核病人的石蜡包埋组织标本进行了多重PCR检测 ,1 93例病理诊断为淋巴结结核、结核性肉芽组织、结核性肉芽肿性炎症病人的标本 ,检测结果符合结核分枝杆菌复合体感…     

The thymus as a target for mycobacterial infections

Mycobacterial infections are among the major health threats worldwide. Ability to fight these infections depends on the host's immune response, particularly on macrophages and T lymphocytes produced by the thymus. Using the mouse as a model, and two different routes of infection (aerogenic or intravenous), we show that the thymus is consistently colonized by Mycobacterium tuberculosis, Mycobacterium avium or Mycobacterium bovis BCG. When compared to organs such as the liver and spleen, the bacterial load reaches a plateau at later time-points after infection. Moreover, in contrast with organs such as the spleen and the lung no granuloma were found in the thymus of mice infected with M. tuberculosis or M. avium. Since T cell differentiation depends, to a large extent, on the antigens encountered within the thymus, infection of this organ might alter the host's immune response to infection. Therefore, from now on, the thymus should be considered in studies addressing the immune response to mycobacterial infection.     

Functional and phenotypic changes in monocytes from patients with tuberculosis are reversed with treatment

Alterations of monocyte/macrophages have been reported in patients with tuberculosis (TB), but their significance is poorly understood. Blood mononuclear cells from patients with different clinical forms of TB, at various times of anti-TB treatment, and healthy tuberculin positive individuals, were double-stained for CD14 plus CD206, TLR-2, IFN-gammaR1, CD40, HLA-DR, CD36 and CD163, and analyzed by flow cytometry. Monocytes were infected with Mycobacterium tuberculosis H37Rv and 24h later the phenotype, induction of necrosis and apoptosis and production of tumor necrosis factor TNFalpha, interleukin (IL)-10 and IL-12p40 were determined. TB patients presented higher percentage of CD14+ cells but lower percentage of CD14+DR+ and CD14+CD36+ cells. Expression of CD14, HLA-DR and CD36 was decreased in TB patients. Normal percentages and expression were restored during anti-TB treatment. Monocytes from TB patients underwent necrosis and apoptosis after M. tuberculosis infection, whereas monocytes from healthy controls exhibited only apoptosis. Anti-TB treatment reverted necrosis. There were no differences between the various clinical forms of TB. In vitro M. tuberculosis infection decreased expression of the membrane molecules studied. HLA-DR and CD36 inhibition correlated with induction of apoptosis. Restoration of monocyte alterations during anti-TB treatment suggests that such alterations may be caused by the high M. tuberculosis load present during active disease.     

Host genetic background affects regulatory T-cell activity that influences the magnitude of cellular immune response against Mycobacterium tuberculosis

Using two mouse strains with different abilities to generate interferon (IFN)-γ production after Mycobacterium tuberculosis infection, we tested the hypothesis that the frequency and activity of regulatory T (Treg) cells are influenced by genetic background. Our results demonstrated that the suppressive activity of spleen Treg cells from infected or uninfected BALB/c mice was enhanced, inhibiting IFN-γ and interleukin (IL)-2 production. Infected C57BL/6 mice exhibited a decrease in the frequency of lung Treg cells and an increased ratio CD4(+):CD4(+)Foxp3(+) cells compared with infected BALB/c mice and uninfected C57BL/6 mice. Moreover, infected C57BL/6 mice also had a decrease in the immunosuppressive capacity of spleen Treg cells, higher lung IFN-γ and IL-17 production, and restricted the infection better than BALB/c mice. Adoptive transfer of BALB/c Treg cells into BALB/c mice induced an increase in bacterial colony-forming unit (CFU) counts. Furthermore, BALB/c mice treated with anti-CD25 antibody exhibited lung CFU counts significantly lower than mice treated with irrelevant antibody. Our results show that in BALB/c mice, the Treg cells have a stronger influence than that in C57BL/6 mice. These data suggest that BALB/c and C57BL/6 mice may use some different mechanisms to control M. tuberculosis infection. Therefore, the role of Treg cells should be explored during the development of immune modulators, both from the perspective of the pathogen and the host.     

Persistence and turnover of antigen-specific CD4 T cells during chronic tuberculosis infection in the mouse

CD4 T cells are critical for resistance to Mycobacterium tuberculosis infection, but how effective T cell responses are maintained during chronic infection is not well understood. To address this question we examined the CD4 T cell response to a peptide from ESAT-6 during tuberculosis infection in the mouse. The ESAT-6(1-20)/IA(b)-specific CD4 T cell response in the lungs, mediastinal lymph nodes, and spleen reached maxima 3-4 wk postinfection, when the bacteria came under the control of the immune response. Once chronic infection was established, the relative frequencies of Ag-specific CD4 T cells were maintained at nearly constant levels for at least 160 days. ESAT-6(1-20)/IA(b)-specific CD4 T cells that responded in vitro expressed activation markers characteristic of chronically activated effector cells and used a limited Vbeta repertoire that was clonally stable in vivo for at least 12 wk. 5-Bromo-2-deoxyuridine incorporation studies indicated a relatively high rate of cell division among both total CD4 and ESAT-6(1-20)/IA(b)-specific CD4 T cells during acute infection, but the degree of 5-bromo-2-deoxyuridine incorporation by both the CD4 T cells and the Ag-specific cells declined at least 3-fold during chronic infection. The data indicate that the peripheral ESAT-6(1-20)/IA(b)-specific CD4 T cell response to M. tuberculosis is characterized during the acute phase of infection by a period of extensive proliferation, but once bacterial control is achieved, this is followed during chronic infection by an extended containment phase that is associated with a persistent response of activated, yet more slowly proliferating, T cells.     

Mycobacterium tuberculosis ESAT6 modulates host innate immunity by downregulating miR-222-3p target PTEN

Tuberculosis (TB) remains a major cause of mortality and morbidity worldwide, and it is instant to discover novel anti-TB drugs due to the rapidly growing drug-resistance TB. Mycobacterium tuberculosis (Mtb) secreted effector ESAT6 plays a critical role in modulation miRNAs to regulate host defense mechanisms during Mtb infection, it can be a possible target for new tuberculosis drugs. The non-tuberculous mycobacteria Mycobacterium smegmatis (M. smegmatis) and Mtb have high gene homology but no pathogenicity. We used ESAT6 to interfere with macrophages or mice infected by M. smegmatis and determined that it enhanced the survival rate of bacteria and regulated miR-222-3p target PTEN. Expression of miR-222-3p reduced and PTEN enhanced with the progression of macrophages infected by M. smegmatis with ESAT6 co-incubation. MiR-222-3p overexpression diminished M. smegmatis survival and upregulated proinflammatory cytokines. VO-Ohpic trihydrate (PTEN inhibitor) reduced M. smegmatis survival and upregulated proinflammatory cytokines in vivo and in vitro, and VO-Ohpic trihydrate reversed the tissue damage of mouse organs caused by ESAT6. These results uncover an ESAT6 dependent role for miR-222-3p and its target PTEN in regulating host immune responses to bacterial infection and may provide a potential site for the development of anti-tuberculosis drugs that specifically antagonize the virulence of ESAT6.     

Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice

We investigated the protective role of immune-sera against reactivation of Mycobacterium tuberculosis infection in SCID mice and found that passive immunization with sera obtained from mice treated with detoxified M. tuberculosis extracts (delivered in liposomes in a composition known as RUTI) exerted significant protection. Our SCID mouse model consisted of aerosol infection by M. tuberculosis, followed by 3 to 8weeks of chemotherapy with isoniazid+rifampicin (INH+RIF) (25 and 10mg/kg, respectively). After infection and antibiotic administration, two groups of mice were treated for up to 10weeks with intraperitoneal passive immunization using hyperimmune serum (HS) obtained from mice infected with M. tuberculosis, treated with chemotherapy (INH+RIF) for 8weeks and inoculated with RUTI (HS group) or with normal serum (CT group). Significant differences were found between HS and CT groups in the number of bacilli in the lungs (3.68+/-2.02 vs. 5.72+/-1.41log(10) c.f.u.), extent of pulmonary granulomatomous infiltration (10.33+/-0.67 vs. 31.2+/-1.77%), and percentage of animals without pulmonary abscesses (16.7% vs. 45.5%). These data strongly suggest a protective role of specific antibodies against lung dissemination of M. tuberculosis infection.